GLPG1205 NEW
| Price | $84 | $207 | $353 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-10 |
Product Details
| Product Name: GLPG1205 | CAS No.: 1445847-37-9 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2026/06/10 |
Product Introduction
Bioactivity
| Name | GLPG1205 |
| Description | GLPG1205 is a potent, orally active GPR84 (G protein-coupled receptor) antagonist with anti-inflammatory activity. GLPG1205 shows good PK/PD characteristics and can be used to study pulmonary fibrosis. |
| In vitro | When GLPG1205 is administered at a concentration of 1 μM for a duration of 5 minutes, it effectively prevents the generation of reactive oxygen species (ROS) triggered by the GPR84 agonist. In TNF-α primed neutrophils, GLPG1205 exhibits strong antagonistic activity against ZQ16-induced ROS, with an IC50 value of 15 nM. Additionally, at a concentration of 0.5 μM, GLPG1205 completely suppresses the ZQ16-induced increase in intracellular calcium levels ([Ca2+]i) in neutrophils[1]. |
| In vivo | GLPG1250 inhibits the increase in MnSOD in lung bronchial epithelial cells and parenchymal macrophages, in the irradiation model. GLPG1205 dose dependently decreases disease activity, histological activity, neutrophil influx and colonic MPO content,in a mouse IBD model. Oral administration of GLPG1250 (30mg/kg;?twice daily for 2 weeks, starts from 7 days post-challenge) greatly reduces the Ashcroft score, in idiopathic pulmonary fibrosis model.?Oral administration of GLPG1250 (30mg/kg;?once daily starts from 18 weeks post irradition) significantly reduces college deposition in the mouse lung[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 5 mg/mL (13.21 mM), Sonication is recommended. DMSO : 45 mg/mL (118.92 mM), Sonication is recommended. 10% DMSO+90% Saline : < 4.5 mg/mL (11.89 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4.5 mg/mL (11.89 mM), Solution. |
| Keywords | GPR84 | GLPG-1205 | GLPG1205 | GLPG 1205 |
| Inhibitors Related | Monomethyl fumarate | Kynurenic acid | Pamoic acid disodium | Azathioprine | CRTh2 antagonist 2 | Fezagepras sodium | Benzyl nicotinate | 1-methoxycyclopropanecarboxylic acid | TUG-1375 | CAY10595 | TUG-424 | Timapiprant |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $84.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY